| Identification | Back Directory | [Name]
CPo3604-01 | [CAS]
951127-25-6 | [Synonyms]
cp03
CPO3
CPo3604-0
CPo3604-01
MK-3102 Intermediate I
Omarigliptin inter. OG-1
Omarigliptin intermediate I
Omarigliptin Intermediate 1
Product NaMe:MK-3102 interMediate
(5S,6R)-5-(Boc-amino)-6-(2,5-difluorophenyl)tetrahydropyran-3-one
tert-butyl N-[(2R,3S)-2-(2,5-difluorophenyl)-5-oxooxan-3-yl]carbamate
tert-Butyl (2R,3S)[2-(2,5-difluoro-phenyl)-5-oxo-tetrahydro-pyran-3-yl]-carbamate
tert-Butyl N-[(2R,3S)-2-(2,5-difluorophenyl)-5-oxo-tetrahydropyran-3-yl]carbamate
tert-butyl [(2R,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pvran-3 yl]carbaMate
tert-butyl ((2R,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbaMate
tert-butyl [(2R,3S)-5-oxo-2-(2,5-difluorophenyl)tetradihydro-2H-pyran-3-yl]carbaMate
Tert-butyl [(2r,3s)-5-oxo-2-(2,5-difluorophenyl) tetrahydro-2h-pyran-3-yl]carbamate
CPo3604-01###tert-butyl ((2R,3R)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate
N-[(2R,3S)-2-(2,5-difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]-CarbaMic acid 1,1-diMethylethyl ester
Carbamic acid, N-[(2R,3S)-2-(2,5-difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]-, 1,1-dimethylethyl ester | [Molecular Formula]
C16H19F2NO4 | [MDL Number]
MFCD20926096 | [MOL File]
951127-25-6.mol | [Molecular Weight]
327.32 |
| Chemical Properties | Back Directory | [Boiling point ]
433.4±45.0 °C(Predicted) | [density ]
1.25±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [pka]
11.00±0.40(Predicted) | [InChI]
InChI=1S/C16H19F2NO4/c1-16(2,3)23-15(21)19-13-7-10(20)8-22-14(13)11-6-9(17)4-5-12(11)18/h4-6,13-14H,7-8H2,1-3H3,(H,19,21)/t13-,14+/m0/s1 | [InChIKey]
OTCULXVRRSCLLI-UONOGXRCSA-N | [SMILES]
C(OC(C)(C)C)(=O)N[C@H]1CC(=O)CO[C@@H]1C1=CC(F)=CC=C1F |
| Hazard Information | Back Directory | [Uses]
N-[(2R,3S)-2-(2,5-Difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]carbamic Acid 1,1-Dimethylethyl Ester is a useful synthetic intermediate in the synthesis of Omarigliptin (O633100); a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor used for the treatment of type 2 diabetes. |
|
|